Regeneron Pharmaceuticals (REGN) announced 36 abstracts across its immunology and inflammation portfolio and pipeline will be presented at the 2026 American Academy of Allergy, Asthma and Immunology, AAAAI, Annual Meeting being held February 27 to March 2 in Philadelphia, Pennsylvania. Highlights include the first presentations from the novel Phase 3 allergen-specific programs demonstrating the potential of a first-in-class approach to addressing burdensome ocular symptoms in adults with cat and birch allergies. New Dupixent analyses across dermatological, respiratory and gastrointestinal diseases will also be presented in collaboration with Sanofi (SNY)
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $975 from $865 at Guggenheim
- Regeneron Targets Early Myeloma: New Phase 3 Trial Pits Linvoseltamab Against Daratumumab
- Regeneron’s REGN9533 Trial Completion Signals Quiet but Important Progress in Clot-Blocking Drugs
- Regeneron’s Expanding AI Use Raises Data Privacy, Regulatory and Market Risks
- Regeneron Broadens Women’s Health Pipeline With New Phase 2 FHA Trial